PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime.
PlasmaGen Biosciences operates one of India’s five plasma fractionation facilities near Bengaluru, which is a critical component in the production of life-saving therapies. The company’s facility is equipped with state-of-the-art technology, enabling it to manufacture high-quality plasma-derived products that cater to the growing demand in the domestic and international markets.
The funding round led by ViNS Bioproducts is a testament to the company’s strong growth potential and its commitment to delivering innovative solutions in the biotechnology sector. With this investment, PlasmaGen plans to expand its manufacturing capabilities, enhance its research and development efforts, and strengthen its market presence.
The Indian biotechnology sector has witnessed significant growth in recent years, driven by government initiatives, increasing demand for innovative therapies, and a thriving startup ecosystem. The sector has attracted significant investments from domestic and international investors, with many companies raising substantial funds to scale their operations and develop new products.
PlasmaGen Biosciences is one of the few companies in India that has made significant strides in the plasma fractionation space. The company’s focus on quality, innovation, and customer satisfaction has earned it a reputation as a reliable partner for pharmaceutical companies and healthcare providers.
The company’s plasma fractionation facility is designed to meet international standards, with a strong emphasis on quality control and assurance. The facility is equipped with advanced equipment and technology, enabling PlasmaGen to manufacture a range of plasma-derived products, including immunoglobulins, albumin, and clotting factors.
The demand for plasma-derived products is increasing globally, driven by the growing prevalence of diseases such as immunodeficiency disorders, bleeding disorders, and infectious diseases. India, with its large patient population and growing healthcare infrastructure, offers significant opportunities for companies like PlasmaGen to cater to the domestic and international markets.
PlasmaGen’s strong investor base, including Eight Roads, FIL Capital, and F-Prime, has played a crucial role in the company’s growth and development. These investors have brought significant expertise and resources to the table, enabling PlasmaGen to scale its operations, expand its product portfolio, and strengthen its market presence.
The latest funding round led by ViNS Bioproducts is expected to further accelerate PlasmaGen’s growth trajectory. With a valuation of over ₹1,500 crore, the company is well-positioned to take on larger competitors and expand its market share.
In conclusion, PlasmaGen Biosciences’ fundraising of ₹150 crore, led by ViNS Bioproducts, is a significant milestone for the company and the Indian biotechnology sector. With a strong investor base, a state-of-the-art manufacturing facility, and a commitment to innovation and quality, PlasmaGen is poised to become a leading player in the global plasma fractionation industry.
As the Indian biotechnology sector continues to grow and evolve, companies like PlasmaGen Biosciences are expected to play a critical role in driving innovation, creating jobs, and improving healthcare outcomes. With the government’s support and the influx of investments from domestic and international investors, the sector is likely to witness significant growth in the coming years.
For more information on PlasmaGen Biosciences and its funding round, please visit: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
